Christine Blank
Will new biosimilars hurt blockbuster autoimmune drug?
Will new biosimilars hurt blockbuster autoimmune drug?
New biosimilars may harm the sales of this autoimmune blockbuster.
FDA okays targeted leukemia treatment
FDA approved a targeted new drug to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
FDA eyes opioids in kids' medicines
FDA eyes opioids in kids' medicines
An FDA committee will review prescription opioid products containing hydrocodone or codeine to treat coughs in children.
Groups praise lawsuit against Walgreens, CVS
Pharmacy and medical organizations lauded a new class action lawsuit against CVS Health and Walgreens, alleging the two pharmacy chains colluded with pharmacy benefit managers (PBMs) to drive up the cost of generic drugs.
FDA warns about contaminated drugs, dietary supplements
FDA warned consumers and health care professionals not to use a certain brand of drugs and dietary supplements that are contaminated.
DEA wants to slash opioid production
The Drug Enforcement Administration wants to slash the production of opioid painkillers by 20% in 2018.
FDA approves novel leukemia, hepatitis C drugs
FDA approved the first treatment for patients with a certain type of acute myeloid leukemia, as well as 2 new drugs to treat hepatitis C.
Amputation risk possible with diabetes drugs, FDA warns
Based on new data from 2 large clinical trials, FDA is warning that these blockbuster type 2 diabetes medications can cause an increased risk of leg and foot amputations.
FDA expands cystic fibrosis treatment
FDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.
New FDA lead ushers in new era
Scott Gottlieb, MD, was sworn in as the new FDA commissioner and ushers in a new era.


View Results